Insights from 2023 ASH Annual Meeting
D

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implications"

By Insights from 2023 ASH Annual Meeting FEATURING Douglas Tremblay
By Insights from 2023 ASH Annual Meeting FEATURING Douglas Tremblay
0 views
January 26, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)

What to Do When Patch Testing is Negative?

Feat. M. Montanez-Wiscovich
23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
24:27
BMFcases

Experts Discuss Pros and Cons of Treatment Approaches in PV

Feat. T. Bat, A. Tefferi
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

17:05
BMFcases

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

Feat. T. Bat, A. Tefferi
06:18
Cleveland Clinic Taussig Cancer Institute

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Feat. A. Gerds
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
18:42
Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

Feat. A. Goldberg
24:48
Indy Hematology Review

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Feat. R. Rampal
08:11
Krisstina Gowin

Counseling Patients With Newly Diagnosed PV or ET

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg